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Introduction: Members of the peptidylarginine deiminase (PAD) family catalyse the posttranslational conversion of
peptidylarginine to peptidylcitrulline. Citrullination of proteins is well described in rheumatoid arthritis (RA), and
hypercitrullination of proteins may be related to inflammation in general. PAD activity has been demonstrated in
various cell lysates, but so far not in synovial fluid. We aimed to develop an assay for detection of PAD activity, if
any, in synovial fluid from RA patients.
Methods: An enzyme-linked immunosorbent assay using human fibrinogen as the immobilized substrate for
citrullination and anti-citrullinated fibrinogen antibody as the detecting agent were used for measurement of PAD
activity in synovial fluid samples from five RA patients. The concentrations of PAD2 and calcium were also determined.
Results: Approximately 150 times lower levels of recombinant human PAD2 (rhPAD2) than of rhPAD4 were required
for citrullination of fibrinogen. PAD activity was detected in four of five synovial fluid samples from RA patients and
correlated with PAD2 concentrations in the samples (r = 0.98, P = 0.003). The calcium requirement for half-maximal
activities of PAD2 and PAD4 were found in a range from 0.35 to 1.85 mM, and synovial fluid was found to contain
sufficient calcium levels for the citrullination process to occur.
Conclusions: We present an assay with high specificity for PAD2 activity and show that citrullination of fibrinogen can
occur in cell-free synovial fluid from RA patients.Introduction
Posttranslational modifications, such as citrullination,
methylation or glycosylation, are common alterations that
modify protein structure and possibly stability, functionality
and antigenicity of proteins. The peptidylarginine deimi-
nases (PADs) are a family of enzymes capable of converting
arginine residues in (poly)peptides to citrullines, a process
known as citrullination. Five PAD isoforms (PADs 1 to 4
and PAD6), with differential cellular and tissue distribution,
have been described in humans [1]. Citrullination regulates
homeostatic processes such as keratinocyte differentiation
[2] and maintenance of myelin sheath insulation [3].* Correspondence: claus.henrik.nielsen@rh.regionh.dk
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stated.Moreover, citrullination is involved in the innate immune
response—that is, by regulation of chemokine activity [4]—
and by formation of neutrophil extracellular traps [5].
Citrullination has been linked to the pathogenesis of
an increasing number of diseases (reviewed in [6]), with
rheumatoid arthritis (RA) being the most intensively
explored example [7]. In RA, PADs play a crucial role in
the generation of the citrullinated proteins targeted by anti-
citrullinated protein antibodies (ACPAs) [7] and citrulli-
nated peptides recognized by autoreactive T cells [8]. Thus,
a major proportion of RA patients carry human leucocyte
antigen molecules containing the “shared epitope” motif [9]
capable of binding citrullinated self-peptides [10]. The dif-
ferent isoforms of PAD have different substrate specificities
[11] and may thus generate different citrullinated peptides
for recognition by self-reactive T cells. Increased levels of
PADs and hypercitrullination of proteins have been linkedtral. This is an Open Access article distributed under the terms of the Creative
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generative conditions such as multiple sclerosis [12] and
Alzheimer’s disease [13].
Activity of PADs has been demonstrated in various cell
lysates, such as muscle, ovary and spinal cord [14]. The
presence of PADs has been shown in synovial fluid from
RA patients as well as from patients with osteoarthritis
(OA) [15]. Although numerous citrullinated proteins have
been described in synovial fluid of RA patients [16], it has
not, to our knowledge, been shown that the conditions ne-
cessary for PADs to be active, including an appropriate
calcium concentration, are met in synovial fluid. Binding
of calcium to PADs alters the conformation of the catalytic
site and thereby PADs’ interaction with various substrates
[17]. Depending on the method of detection, half-maximal
PAD activity has been reported at calcium concentrations
ranging from 40 μM to 3.3 mM [14,18,19]. The low intra-
cellular calcium levels of resting cells indicate that intra-
cellular citrullination occurs only after cell stimulation or
after membrane disintegration as a result of cell death
[20]. Both intracellular proteins (for example, vimentin)
and extracellular proteins (for example, fibrinogen) are
targets for ACPAs in RA [21,22], and the citrullinated
forms of vimentin and fibrinogen and fibrin have been
shown to enhance a proinflammatory immune response in
ACPA-positive patients [23-25]. It is unclear which citrul-
linated antigens are more important in the pathogenesis.
Several methods for measurement of PAD activity have
been described. These assays usually measure conversion
of arginine to citrulline in synthetic peptides by means of
colorimetry [26], high-performance liquid chromatography,
fluorometry [27], fluorescence quenching [28], spectropho-
tometry [29] and antibody-based detection [14] and differ
with respect to sensitivity and applicability for biological
samples [30]. None of them are capable of discriminating
between citrullination caused by the different PAD iso-
types, however.
Different substrate specificities have been demonstrated
for PAD2 and PAD4 [11,31], with PAD4 showing a more
restricted pattern than PAD2. In the present study, we
exploited these differences to develop an assay, measuring
citrullination of fibrinogen, with almost complete specifi-
city for PAD2 activity. This assay provides new insight into
the calcium requirement of PAD2 and PAD4, and we used
it to determine the catalytic activity of PADs in synovial
fluid samples.
Methods
Collection of synovial fluid from rheumatoid arthritis
patients
Synovial fluid samples were obtained during joint aspir-
ation for therapeutic reasons from five patients with
RA (four women). The patients fulfilled the American
College of Rheumatology criteria for the diagnosis of RA[32] and gave us their written informed consent for par-
ticipation. The mean age (range) of the patients was 58.6
(45 to 69) years. Four patients were positive for ACPAs.
All samples were stored at −80°C until use. Before analysis,
synovial fluid samples were treated with hyaluronidase
(Hylase Dessau; Riemser Arzneimittel, Greifswald, Germany)
at 37°C for 30 minutes and centrifuged at 3,500 rpm
for 10 minutes. The study was approved by the local ethics
committee of the Institute of Rheumatology, Charles
University Prague, Czech Republic.
Quantification of Ca2+ concentration in synovial fluids
Synovial fluid calcium concentrations were determined
using a colorimetric assay based on formation of a
chromogenic complex between free calcium and o-cre-
solphthalein (Abcam, Cambridge, UK). Absorbance was
measured at 575 nm using the SPECTROstar Nano mi-
croplate reader (BMG Labtech, Ortenberg, Germany).
Quantification of peptidylarginine deiminase 2
concentration in synovial fluids
The PAD2 content in synovial fluid samples was deter-
mined in a previously described assay [33]. In brief,
enzyme-linked immunosorbent assay (ELISA) plates were
coated with anti-PAD2 monoclonal antibody (mAb) DN2
(1 μg/ml) overnight at 4°C. Synovial fluid samples were di-
luted twofold from 1:10 to 1:80 in dilution buffer (phos-
phate-buffered saline (PBS), 0.5% Tween 20, 2% bovine
serum (Sigma, St Louis, MO, USA), 20 μg/ml Mouse
Immunoglobulin G Isotype Control (Novus Biologicals,
Cambridge, UK), pH 7.4) and incubated for 2 hours at
room temperature. Biotinylated anti-PAD2 mAb DN6
(1 μg/ml) was added, followed by incubation with
streptavidin-conjugated horseradish peroxidise (HRP;
Invitrogen, Carlsbad, CA, USA) and development with
o-phenylenediamine substrate (Kem-En-Tec Diagnos-
tics, Taastrup, Denmark). All standards and samples
were measured in duplicates. Absolute PAD2 concen-
trations were calculated by regression analysis for the
standard curve using four-parameter logistic curve-
fitting by means of MARS software (BMG Labtech).
Peptidylarginine deiminases
Recombinant human PAD2 (rhPAD2) and rhPAD4 were
produced, purified and defined by means of mass con-
centration, as described previously [34]. Commercially
available rhPAD enzymes ModiQuest (MQ) rhPAD2
(MQ21.101; 4.88 mU/ml) and MQ rhPAD4 (MQ21.102;
58.3 mU/ml) were all purchased from ModiQuest, Oss,
Netherlands.
Antibodies
Monoclonal mouse anti-citrullinated fibrinogen (anti-
cFib) (clone 20B2) and human anti-cFib (clone 1 F11)
Damgaard et al. Arthritis Research & Therapy  (2014) 16:498 Page 3 of 7were purchased from ModiQuest (MQ13.102 and
MQR2.101, respectively). HRP-conjugated polyclonal
rabbit anti-mouse antibodies were obtained from Dako
(Glostrup, Denmark).
In vitro citrullination of fibrinogen
Fibrinogen (Calbiochem, Darmstadt, Germany) was incu-
bated at a final concentration of 1.0 mg/ml with rhPAD2
(60 ng/ml) raised in-house in citrullination buffer
(100 mM Tris-HCl, 10 mM CaCl2, 1 mM dithiothreitol
(DTT), pH 7.5) overnight at 37°C. Mobility changes of
citrullinated fibrinogen were confirmed with SDS-PAGE.
Enzyme-linked immunosorbent assay activity
Nunc MaxiSorp ELISA plates (Roskilde, Denmark) were
coated overnight at 4°C with 100 μl of fibrinogen (1.0 μg/
ml) in coating buffer (30 mM Na2CO3, 70 mM NaHCO3,
pH 9.6). Wells were washed thrice and blocked in washing
buffer A (Tris-buffered saline, 0.05% Tween 20, pH 7.4) for
20 minutes at room temperature. In general, rhPADs were
diluted in citrullination buffer and incubated for 3 hours at
room temperature for determination of activity and cal-
cium dependency. Synovial fluid samples were applied di-
luted 1:3 in various buffers (Tris-HCl, 1 mM DTT with or
without 10 mM CaCl2 or ethylenediaminetetraacetic acid
(EDTA)). Following three washes in washing buffer B (PBS,
0.05% Tween 20, pH 7.4), the wells were incubated for
90 minutes at room temperature with 100 μl of murine
anti-cFib antibody in washing buffer B. After three further
washes, the wells were incubated with 100 μl of HRP-
conjugated polyclonal rabbit anti-mouse immunoglobulin
antibodies (Dako) diluted 1:1,000 in washing buffer B. Fi-
nally, the plates were washed thrice in washing buffer B
and incubated with 0.4 mg/ml o-phenylenediamine in de-
veloping buffer (35 mM citric acid, 65 mM Na2PO4,
pH 5.0). After 10 minutes, the colour reaction was stopped
with 1.0 M H2SO4, and optical density (OD) was measured
at 490 to 650 nm using the SPECTROstar Nano micro-
plate reader (BMG Labtech). Data were processed using
MARS software (BMG Labtech). This procedure was
modified as indicated in the Results section.
Statistical analysis
All experiments are shown as means and ranges of du-
plicate measurements. Pearson’s correlation (r) coeffi-
cient and levels of significance were determined using
GraphPad Prism 5.0 software (GraphPad Software, La
Jolla, CA, USA).
Results
Assay for detection of citrullinated human fibrinogen
We developed an assay for citrullination of immobilized
human fibrinogen using a mAb specific for cFib as the
detecting antibody (Figure 1A). Immobilized humanfibrinogen was incubated with different rhPADs for vari-
ous periods. Citrullination of fibrinogen was detectable
as early as after 2.5 minutes, and the highest signals,
without reaching a plateau, were observed after 4 hours
of incubation (Figure 1B). A substantial degree of citrul-
lination occurred after 3 hours of incubation, which was
selected for subsequent studies.
Comparison between enzymatic activities of
peptidylarginine deiminases 2 and 4
The assay proved markedly more sensitive to PAD2 ac-
tivity than PAD4 activity, in that approximately 150
times more in-house rhPAD4 was required to achieve an
extent of fibrinogen citrullination comparable to that
catalysed by in-house rhPAD2 (Figure 2A). The lower
limit of detection (LOD), defined as background plus 3
times standard deviation (SD), was 0.46 ng/ml for
rhPAD2 and 234 ng/ml for rhPAD4. A similar pattern
was observed for the recombinant enzymes obtained
from ModiQuest, where ~20 times more units of
MQPAD4 than of MQPAD2 were needed for similar
levels of Fib citrullination (Figure 2B). The LOD for MQ
rhPAD2 was 0.08 mU/ml and 1.25 mU/ml for MQ
rhPAD4. Using a different antibody for detection, that is
human anti-cFib antibody (clone 1 F11), we obtained simi-
lar preference for PAD2-mediated citrullination (data not
shown).
Calcium dependency of peptidylarginine deiminases 2
and 4
The enzymatic properties of four different PAD prepara-
tions were tested at calcium concentrations ranging
from 50 μM to 10 mM (Figure 3). No activity of any of
the enzymes was observed below 110 μM calcium. Max-
imal activities were observed in the range from around
1.5 to 10 mM CaCl2. MQ rhPAD2, in-house rhPAD2
and in-house rhPAD4 showed similar requirements for
calcium. The half-maximal activities of these enzymes
were observed at CaCl2 concentrations of 0.35 mM,
0.46 mM and 0.55 mM, respectively. MQ rhPAD4 required
markedly higher calcium concentrations for citrullination,
showing half-maximal activity at 1.85 mM CaCl2.
Peptidylarginine deiminase activity can be determined in
synovial fluid from patients with rheumatoid arthritis
Synovial fluid samples from five patients with RA (SF1
to SF5) were tested for PAD activity. The calcium con-
tent in the samples ranged from 1.5 to 2.5 mM (data not
shown), which was well within the range for PAD to be
active, as shown above. Four of the five samples were
capable of citrullinating fibrinogen after 1:3 dilution in
Tris buffer, yielding a final calcium concentration of 0.5
to 0.83 mM (black columns in Figure 4A). Optimizing
the enzymatic properties by addition of 10 mM CaCl2 to
Figure 1 In situ citrullination of human fibrinogen. (A) Fibrinogen (Fib) or citrullinated fibrinogen (cFib) was immobilized to enzyme-linked
immunosorbent assay (ELISA) plates at a concentration of 1 μg/ml. Increasing concentrations of the anti-cFib monoclonal antibody (mAb; clone
20B2) were added, followed by addition of enzyme-conjugated rabbit anti-mouse immunoglobulin antibodies and o-phenylenediamine substrate.
All data points represent means and ranges of duplicate measurements of optical density at 490 nm. (B) ELISA plates were coated with 1.0 μg/ml
human fibrinogen and incubated with citrullination buffer including recombinant human peptidylarginine deiminase (rhPAD) enzyme, ModiQuest
(MQ) PAD2 (8 mU/ml), rhPAD2 (42 ng/ml), MQPAD4 (49 mU/ml) or rhPAD4 (1,500 ng/ml). Shown is the activity as a percentage of the maximal
activity obtained for each enzyme, corresponding to the activity at 4 hours. Anti-cFib mAb was used at a concentration of 0.5 μg/ml, as
determined from the graph shown in (A). Symbols and error bars represent means and ranges of duplicate measurements.
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ples (SF2, SF3 and SF5) and to a minor extent in one
sample (SF1). Addition of the calcium chelator EDTA
eliminated activity in all samples (grey and white col-
umns in Figure 4A, respectively).
The five samples all contained soluble PAD2, at con-
centrations ranging from 12 ng/ml to 35 ng/ml (x-axis
in Figure 4B), and the PAD activity of the samples corre-
lated with the PAD2 content (Figure 4B).
Discussion
The presence of PAD2 and PAD4 have been demon-
strated in synovium from RA and OA patients [15], and
multiple citrullinated proteins are known to be presentFigure 2 Comparison between enzymatic activities of peptidylarginin
were coated with 1.0 μg/ml human fibrinogen. (A) Recombinant human p
used for citrullination at mass concentrations ranging from 0.1 ng/ml to 15
enzymes were used in units ranging from 0.1 mU/ml to 100 mU/ml. Follow
used for detection of citrullinated fibrinogen. Duplicate measurements of oin synovial fluid from RA patients [16]. It has not been
established, however, if the requirements for the two iso-
forms to be active are met in the synovium for citrullina-
tion to take place in situ. Alternatively, citrullinated
proteins may be translocated to synovial fluid from other
sites. Insight into the absolute and relative activities of
different PAD isoforms in synovial fluid in various types
of joint inflammation may lead to a better understanding
of the pathophysiology of the diseases and may be diag-
nostically useful.
The assay for citrullination of human fibrinogen pre-
sented here showed a strong preference for detection of
PAD2 activity compared to PAD4 activity. We modified an
already existing antibody-based ELISA [14] by changinge deiminases 2 and 4. Enzyme-linked immunosorbent assay plates
eptidylarginine deiminase 2 (rhPAD2) or rhPAD4 raised in-house were
μg/ml. (B) Commercially available ModiQuest (MQ) PAD2 or MQPAD4
ing a 3-hour citrullination period, the anti-cFib mAb (0.5 μg/ml) was
ptical density (OD) at 490 nm are shown as mean and range.
Figure 3 Calcium dependency of peptidylarginine deiminases. Enzyme-linked immunosorbent assay plates were coated with 1.0 μg/ml
human fibrinogen and incubated with four different recombinant human peptidylarginine deiminase (rhPAD) preparations: ModiQuest (MQ)
PAD2 (8 mU/ml), rhPAD2 (42 ng/ml), rhPAD4 (1,500 ng/ml) or MQPAD4 (49 mU/ml). Dithiothreitol was added at a concentration of 1.0 mM, and
CaCl2 was added at concentrations ranging from 50 μM to 10 mM. Following 3 hours of incubation, citrullination was measured using mouse
anti-cFib monoclonal antibody (0.5 μg/ml). Shown is the activity as a percentage of maximal activity for each enzyme. Symbols and error bars
represent means and ranges of duplicate measurements.
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full-length fibrinogen. Citrullinated fibrinogen is a well-
established autoantigen in RA [22], with approximately
two-thirds of RA patients having autoantibodies against
this modified self-antigen [35]. It is well established that
PAD2 and PAD4 citrullinate fibrinogen to different de-
grees and target different arginine residues [11,31]. The
detecting antibody used in the present study (clone 20B2)
apparently recognizes an epitope on fibrinogen that is
preferentially citrullinated by PAD2. Therefore, it cannot
be firmly concluded that PAD2 is more potent than PAD4.Figure 4 Peptidylarginine deiminases activity in synovial fluid sample
from five rheumatoid arthritis patients were applied on enzyme-linked imm
dilution into Tris buffer with 1 mM dithiothreitol (DTT; black columns), Tris
buffer containing 1 mM DTT and 10 mM ethylenediaminetetraacetic acid (
monoclonal mouse anti-citrullinated fibrinogen (anti-cFib) (0.5 μg/ml) was u
(PAD) activity is presented as optical density (OD) at 490 nm of duplicated m
activity in the five SF samples diluted 1:3 in citrullination buffer containing 1
dotted line). Pearson’s correlation coefficients (r) and levels of significance aThe main finding of our study is that PAD activity was
present in four of five synovial fluid samples from RA pa-
tients. In accordance with the PAD2 specificity of the
assay, the PAD activity of the samples correlated with their
PAD2 content. This finding does not exclude PAD4 activ-
ity in synovial fluid, however. Pure synovial fluid could not
be applied to the assay, owing to the high viscosity of the
samples, so it was necessary to apply a threefold dilution
of the samples. The calcium concentration of the samples
fell below the 1.5 mM required for optimal activity. There-
fore, the activity observed after dilution in buffers from rheumatoid arthritis patients. (A) Synovial fluid (SF) samples
unosorbent assay plates coated with fibrinogen (1 μg/ml) after 1:3
buffer containing 1 mM DTT and 10 mM CaCl2 (grey columns) or Tris
EDTA; white columns). Following a 3-hour incubation period, the
sed for detection of citrullinated fibrinogen. Peptidylarginine deiminase
easurements. (B) Association between PAD2 concentration and PAD
0 mM CaCl2 (grey circles, solid line) or no additive calcium (black circles,
re shown.
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ably more closely reflects the activity of untreated syn-
ovial fluid.
We found a pronounced calcium dependency of PAD2
and PAD4, which both required calcium concentrations
above 100 μM to be active. Some investigators have
demonstrated half-maximal activity of rabbit PAD2 and
rhPAD4 around 40 to 80 μM [14,18], whereas others
have found roughly tenfold higher concentrations (200
to 750 μM) [11,29,36], in agreement with our findings.
In a recent study, investigators found half-maximal activity
of human PAD4 to be as high as 3.3 mM [19]. Use of differ-
ent substrates in various assays or different enzyme purifi-
cation procedures may account at least in part for these
differences. Presumably, intracellular calcium concentra-
tions above 100 μM can be achieved only in situations of
pronounced membrane disruption after serious cell damage
or death, and not even during apoptosis [37,38]. Factors
other than calcium may enhance the catalytic properties of
PADs, rendering intranuclear and/or intracellular activity
possible. Thus, ATP induces intracellular, PAD2-mediated
citrullination in mast cell cultures and facilitates release of
citrullinated proteins and PAD2 itself [20].
Conclusions
We have developed an assay to measure activity of PADs
using a RA autoantigen—fibrinogen. The assay is highly
specific for PAD2 activity, and we demonstrate catalytic
activity in four of five samples as well as soluble PAD2
content in five of five synovial fluid samples from RA patients.
Thus, citrullination apparently can take place extracellularly
within inflamed joints, contributing to an enhanced local
inflammatory response in ACPA-positive RA patients.
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